Comparative Botulinum Toxin Injection Strategies Beyond the Masseter for Bruxism: A Scoping Review
4 affiliations
- 1Division of Neurology, Department of Internal Medicine, School of Medicine, Walailak University, Nakhon Si Thammarat 80160, Thailand
- 2Department of Otorhinolaryngology, Thung Song Hospital, Nakhon Si Thammarat 80110, Thailand
- 3Department of Dermatology, Jigme Dorji Wangchuck National Referral Hospital, Thimphu 11001, Bhutan
- 4Division of Dermatology, Department of Internal Medicine, School of Medicine, Walailak University, Nakhon Si Thammarat 80160, Thailand
Abstract
Background: Botulinum toxin type A is used to reduce excessive masticatory muscle activity in bruxism, but whether extending injection beyond the masseter provides additional benefit remains uncertain. This scoping review aimed to map comparative evidence on expanded botulinum toxin muscle targeting for bruxism and assess whether available studies provide evidence of incremental clinical benefit beyond masseter-only injection. Methods: PubMed, Scopus, the Cochrane Central Register of Controlled Trials, and the World Health Organization International Clinical Trials Registry Platform were searched from inception to 3 August 2026. Eligible studies directly compared botulinum toxin injection strategies differing in the muscles targeted. Data were charted and synthesized descriptively. The protocol was prospectively registered with INPLASY (INPLASY202680008). Results: Five small randomized trials involving 133 participants were included, of whom 116 contributed to the comparative analyses. Expanded strategies added the temporalis, anterior digastric, lateral pterygoid, or medial pterygoid. Additional clinical benefit of broader targeting was not clearly demonstrated, although some studies reported greater reductions in activity of the additionally injected muscle. In all studies, the masseter dose was held constant while additional muscles were injected, resulting in higher total toxin doses and preventing separation of anatomical targeting effects from dose escalation. Safety evidence was insufficient because reporting was limited and heterogeneous, and the small overall sample precluded adequate characterization of the safety profile. Conclusions: The available evidence is preliminary and insufficient to determine whether routinely extending botulinum toxin injection beyond the masseter provides additional clinical benefit. Future adequately powered, dose-controlled trials should prioritize patient-important outcomes and distinguish the effects of anatomical targeting from total toxin dose.
Related
- Bulging of the Masseter Muscle Following Botulinum Neurotoxin Type A Injection
- Ultrasonographic evaluation of the association between gonial appositional bone changes and masseter muscle thickness and elasticity in bruxism
- Effect of the rs12249854 Polymorphism in the HECTD2 Gene and Selected Clinical Variables on the Response to Intradetrusor Injection of Botulinum Neurotoxin Type A in Female Patients with Overactive Bladder: A Single-Center Prospective Study
- Adjunctive extracorporeal shock wave therapy after botulinum toxin type A injection for post-stroke spasticity: a systematic review and three-level meta-analysis
- Environmental noise pollution and its association with temporomandibular joint disorders, malocclusion, and bruxism: A Comparative cross-sectional study of adults in high-traffic and low- traffic areas
BibTeX
@article{siriarchawawat2026comparative,
title = {{Comparative Botulinum Toxin Injection Strategies Beyond the Masseter for Bruxism: A Scoping Review}},
author = {Doungkamol Siri-Archawawat and Arunrat Dumkliang and Chime Eden and Weeratian Tawanwongsri},
journal = {Journal of clinical medicine},
year = {2026},
month = oct,
doi = {10.3390/jcm15197712},
url = {https://europepmc.org/article/PMC/PMC13665912},
note = {CC BY},
}
RIS
TY - JOUR
TI - Comparative Botulinum Toxin Injection Strategies Beyond the Masseter for Bruxism: A Scoping Review
AU - Doungkamol Siri-Archawawat
AU - Arunrat Dumkliang
AU - Chime Eden
AU - Weeratian Tawanwongsri
PY - 2026
DA - 2026/10/01
JO - Journal of clinical medicine
DO - 10.3390/jcm15197712
UR - https://europepmc.org/article/PMC/PMC13665912
AB - Background: Botulinum toxin type A is used to reduce excessive masticatory muscle activity in bruxism, but whether extending injection beyond the masseter provides additional benefit remains uncertain. This scoping review aimed to map comparative evidence on expanded botulinum toxin muscle targeting for bruxism and assess whether available studies provide evidence of incremental clinical benefit beyond masseter-only injection. Methods: PubMed, Scopus, the Cochrane Central Register of Controlled Trials, and the World Health Organization International Clinical Trials Registry Platform were searched from inception to 3 August 2026. Eligible studies directly compared botulinum toxin injection strategies differing in the muscles targeted. Data were charted and synthesized descriptively. The protocol was prospectively registered with INPLASY (INPLASY202680008). Results: Five small randomized trials involving 133 participants were included, of whom 116 contributed to the comparative analyses. Expanded strategies added the temporalis, anterior digastric, lateral pterygoid, or medial pterygoid. Additional clinical benefit of broader targeting was not clearly demonstrated, although some studies reported greater reductions in activity of the additionally injected muscle. In all studies, the masseter dose was held constant while additional muscles were injected, resulting in higher total toxin doses and preventing separation of anatomical targeting effects from dose escalation. Safety evidence was insufficient because reporting was limited and heterogeneous, and the small overall sample precluded adequate characterization of the safety profile. Conclusions: The available evidence is preliminary and insufficient to determine whether routinely extending botulinum toxin injection beyond the masseter provides additional clinical benefit. Future adequately powered, dose-controlled trials should prioritize patient-important outcomes and distinguish the effects of anatomical targeting from total toxin dose.
SN - 2077-0383
ER -